Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Tiantan Biological Products Current Ratio?
Beijing Tiantan Biological ProductsSHSE:600161 75 Current Ratio is 8.82 as of Mar. 2026, which is 48% above its 10-year median of 5.97. GuruFocus rates SHSE:600161 with a GF Score™ of 75/100 and a GF Value™ of ¥23.94 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Beijing Tiantan Biological Products ranks better than 74.27% on this metric.
Beijing Tiantan Biological Products has a current ratio of 8.82. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
SHSE:600161'
s Current Ratio Range Over the Past 10 Years
Min: 1.4 Med: 5.97 Max: 13.51
Current: 8.82
During the past 13 years, Beijing Tiantan Biological Products's highest Current Ratio was 13.51. The lowest was 1.40. And the median was 5.97.
SHSE:600161's Current Ratio is ranked better than 74.27% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs SHSE:600161: 8.82
Beijing Tiantan Biological Products (SHSE:600161) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Beijing Tiantan Biological Products Current Ratio Related Terms
Beijing Tiantan Biological Products Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tiantan Biological Products Current Ratio Chart
SHSE:600161 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Beijing Tiantan Biological Products's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tiantan Biological Products Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's Current Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Tiantan Biological Products's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tiantan Biological Products (SHSE:600161) has a Current Ratio of 8.82 as of Mar. 2026. This is 48% above median its historical median of 5.97. Over the past decade, Beijing Tiantan Biological Products' Current Ratio has ranged from 1.40 to 13.51. According to the industry distribution chart, Beijing Tiantan Biological Products ranks #363 out of 1411 companies in the Biotechnology industry, placing it in the top 25.7%.
Is Beijing Tiantan Biological Products' Current Ratio too high?
Beijing Tiantan Biological Products' current Current Ratio of 8.82 is 48% above median its 10-year median of 5.97. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 13.51. The Biotechnology industry median Current Ratio is 3.88. Beijing Tiantan Biological Products' value of 8.82 is 127.3% above this industry median. Based on the distribution chart, Beijing Tiantan Biological Products ranks #363 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beijing Tiantan Biological Products has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tiantan Biological Products ranks #363 out of 1411 companies for Current Ratio. This puts Beijing Tiantan Biological Products in the upper half of its industry. The industry median Current Ratio is 3.88. Beijing Tiantan Biological Products' value of 8.82 is 127.3% above this benchmark. Historically, Beijing Tiantan Biological Products' own Current Ratio has ranged from 1.40 to 13.51 over the past decade. While the company's 10-year median is 5.97 vs. the industry median of 3.88, Beijing Tiantan Biological Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tiantan Biological Products's current Current Ratio of 8.82 is 127.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tiantan Biological Products's current Current Ratio is 8.82, which is 48% above median its own 10-year median of 5.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.94, compared to a current price of ¥12.95 — trading 45.9% below its estimated fair value. The current Current Ratio is 8.82, which is 48% above median its 10-year median of 5.97 and 127.3% above the Biotechnology industry median of 3.88. Beijing Tiantan Biological Products' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current Current Ratio is 8.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued.
The current stock price of ¥12.95 is trading 45.9% below its estimated GF Value™ of ¥23.94.
GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.
Key valuation signals for SHSE:600161:
Current Ratio: 8.82 (48% above median its 10-year median of 5.97)
GF Value™: ¥23.94 vs. price of ¥12.95 (45.9% below fair value)
Industry Position: 127.3% above the Biotechnology median (#363 of 1411)
No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tiantan Biological Products Business Description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
75GF Score
Get the complete analysis for SHSE:600161
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600161 has been successfully added to your 
